logo
logo

Immunos Therapeutics Raises $74 Million Series B Financing Round

Jun 07, 2022•over 3 years ago

Amount Raised

$74 Million

Round Type

series b

Description

- New investors Samsara, Lightspeed, Gimv, and Mission BioCapital further strengthen investor base and expand transatlantic footprint

Company Information

Company

Immun Os

About

ImmunOs is also developing antibodies to block the activation of specific HLA protein molecules associated with autoimmune diseases. ImmunOs’ lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and activates anti-tumor responses.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech